Published in Vaccine Weekly, December 28th, 2005
This follows an initial phase I safety and immunogenicity trial in healthy young adults that commenced in July and is the next step in the company's clinical development plan for this vaccine candidate.
C. difficile infection, which is characterized by diarrhea and colitis, is one of the most common hospital-acquired infections around the world. A hyper-virulent, hyper-toxigenic strain of C. difficile has recently emerged and is believed to be responsible for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly